nuvasive inc (NUVA) Key Developments
NuVasive, Inc. Announces the U.S. Launch of ALIF ACR
Dec 17 13
NuVasive, Inc. announced the United States launch of ALIF ACR (Anterior Lumbar Interbody Fusion - Anterior Column Realignment). ALIF ACR is focused on correcting the sagittal plane imbalance that results from advanced degeneration. The innovative product offers surgeons a familiar ALIF technique to increase alignment where 80% of sagittal balance exists, between L4 and S1. ALIF ACR is designed to achieve the same correction capabilities as traditional techniques, while providing the benefits associated with less invasive anterior approaches. The hyperlordotic implants developed for the ALIF ACR procedure are the Company's latest innovative advancement in an effort to improve sagittal plane deformity correction. Typical ALIF implants only offer 8 to 15 degrees of lordosis, which presents a challenge when attempting to restore natural lumbar lordosis. The implants developed for the ALIF ACR procedure offer a 20-degree and 30-degree hyperlordotic footprints and may improve sagittal balance restoration capabilities. The ALIF technique has a rich clinical history and is an accepted procedure for treating certain pathologies of the lumbar spine. Anterior approaches, like ALIF, obtain access to the disc space from the front of the spine. Traditional correction techniques require muscle stripping, and are often associated with significant morbidity, prolonged operative times, neurological complications, high blood loss, and lengthy recovery times.
NuVasive, Inc. Announces Appointment of Gregory T. Lucier to the Board of Directors
Dec 4 13
NuVasive, Inc. announced that Gregory T. Lucier has been named to its Board of Directors. Lucier is Chairman and Chief Executive Officer of Life Technologies Corporation.
NuVasive, Inc. to Commemorate the Official Relocation and Expansion of UK Office at Elstree
Nov 27 13
NuVasive, Inc. will hold media tours to commemorate the official relocation and expansion of the company's UK office at Elstree. The modern two-story, 7,500-square-foot facility adds office space, increases warehousing capabilities, and provides dedicated space for staffing, training and surgeon events.
NuVasive, Inc. Presents at NASDAQ OMX 30th Annual International Investor Program in London, Dec-03-2013 09:30 AM
Nov 21 13
NuVasive, Inc. Presents at NASDAQ OMX 30th Annual International Investor Program in London, Dec-03-2013 09:30 AM. Venue: The Waldorf Hilton, Aldwych, London, WC2B 4DD, United Kingdom.
NuVasive, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Revises Earnings Guidance for the Full Year 2013
Oct 29 13
NuVasive, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported revenue of $169.2 million, a 14.0% increase over the $148.4 million for the third quarter 2012. Income before income taxes was $8.1 million compared with $6.2 million a year ago. Net income was $7.3 million compared with $2.1 million a year ago. Net income attributable to the company was $7.5 million or $0.16 per diluted share compared with $2.4 million or $0.05 per diluted share a year ago. Non-GAAP earnings were $18.3 million or $0.39 per diluted share.
For the nine months, the company's revenue was $494.4 million compared with $454.5 million a year ago. Income before income taxes was $1.2 million compared with $12.98 million a year ago. Net income was $1.1 million compared with $5.2 million a year ago. Net income attributable to the company was $1.9 million or $0.04 per diluted share compared with $5.9 million or $0.13 per diluted share a year ago. Net cash provided by operating activities was $70.1 million compared with $99.5 million a year ago. Purchases of property and equipment were $38.0 million compared with $35.7 million a year ago. Non-GAAP earnings were $39.6 million or $0.85 per diluted share.
For the year 2013, the company expects revenue of approximately $670 million, up from prior guidance of $655 million, GAAP earnings per share of approximately $0.07, up from prior guidance of a loss per share of $0.09, non-GAAP EPS of approximately $1.14, up from prior guidance of $1.00, non-GAAP operating margin of approximately 14.5%, up from prior guidance of 14%, GAAP effective tax expense rate of approximately 40%, compared to a tax benefit rate of approximately 30% previously. The company also expects GAAP gross margin of 73.8% compared with previous guidance of 73.8%.